WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES

Checking

 

Vertex Pharmaceuticals Incorporated VRTX

NasdaqPharmaceuticalsFinancials to Sep 30, 2026 · Updated Nov 11, 2026

On Stock Analysis · affiliate link
VRTX financials
Moat score
99
ROIC
19.1%
P/E
34.9
EV/EBIT
31.0
FCF yield
2.3%
Dividend yield
0.0%
Market cap
$138.9B

Moat ranks

Score rankTied #9 of 396
Durabilitydurable
Market structureQuasi-Monopoly
Pricing powerstrong

Balance sheet

9/30/26
$BDec 31Sep 30
Cash5.15.0
Securities1.51.3
Long-term securities5.73.5
Debt0.04.5
Net cash12.35.3
Equity18.720.9
Leverage
Debt / EBITDA
0.99×
Debt / equity
0.22×
Leases (12/31/25)
$2.0B
Capital
Diluted shares
255M
Book value / share
$81.93
Price / book
6.6×
Net cash / share
$20.86
Market cap
$138.9B
Enterprise value
$133.5B

Per-share record

Fiscal years and TTM
Scale
−$20$0$20$40$60'16'17'18'19'20'21'22'23'2446.52'2550.75TTM
Revenue per shareCash flow per share

Key indicators

Latest: Q3 '26
IndicatorLatestVs year agoLast 8 quarters
Revenue growth11.8%+0.9 pts
Operating margin20.7%-17.8 pts
FCF margin15.9%-21.2 pts
Capex / revenue2.8%-0.5 pts
CF product revenue$3.3B–
TRIKAFTA/KAFTRIO revenue$2.4B-8%
ALYFTREK revenue$706M+186%
CASGEVY revenue$99M+487%
JOURNAVX revenue$58M+197%

Margins and growth from reported quarters; company KPIs as reported in results releases.

About VRTX

Vertex sells medicines for cystic fibrosis, inherited blood disorders, acute pain and, since September 2026, acromegaly. CF supplied 96.2% of June-quarter product sales and funds diversification.

Revenue mix
Cystic Fibrosis CFTR Modulators 96.2%Hemoglobinopathies Gene Therapy (CASGEVY) 2.3%Acute Pain (JOURNAVX) 1.5%Rare endocrine diseases (PALSONIFY) 0.0%
  • IP Choke Point

    Patents protect TRIKAFTA/KAFTRIO through 2037 and ALYFTREK through 2039.

  • Long Term Contracts

    An extended long-term NHS England reimbursement agreement supports paid access to established CF medicines.

  • Biologic regulatory exclusivity

    CASGEVY has 12 years of US biologic regulatory exclusivity from its 2023 approval, protecting its own dossier through 2035.

  • IP Choke Point

    Product and manufacturing patents restrict copying of CASGEVY, but important CRISPR platform licences are non-exclusive or co-exclusive.

Timeline
  1. Oct 20, 2026

    Daniel Brennan, former Boston Scientific CFO, joined the board and Audit and Finance Committee; board expanded to eleven members. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000278/vrtx-20261020.htm (October 20, 2026).

  2. Mar 31, 2025 · Impairment charge −$379M

    Vertex stopped advancing VX-264 and wrote off the acquired research asset. This non-cash loss signals a failed diabetes programme, not weaker CF sales.

  3. Dec 31, 2024 · Full year · One-off charge −$198M

    Cash settlement of unvested Alpine employee awards produced $165.0 million of R&D and $32.6 million of selling and administration expense. This deal cost is separate from the acquired research asset.

  4. Jun 30, 2024 · One-off charge −$4.4B

    Alpine's povetacicept research asset was expensed on acquisition because it had no alternative use. This non-deductible purchased asset drove the reported loss and operating cash outflow; it produced no ordinary income-tax deduction.

  5. Dec 31, 2023 · Full year · One-off charge −$243M

    Entrada upfront and milestone payments bought access to a myotonic dystrophy research programme. The $24.9 million equity investment is a separate asset and is excluded.

Financial record

Fiscal year2016201720182019202020212022202320242025TTMTrendChange 2016–25
Per share ($)
Revenue6.969.8311.7615.9723.5629.1434.4737.8942.7346.5250.75+23.5%/yr
Cash flow0.963.344.906.0212.3510.1715.9413.58-1.9114.0814.48+34.7%/yr
Earnings-0.461.048.094.5110.299.0112.8213.89-2.0815.3215.58–
Free cash flow0.732.944.535.7311.379.2715.1512.81-3.0612.3812.55+36.9%/yr
Capex0.230.390.370.290.990.900.790.771.151.701.93+24.8%/yr
Dividends0.000.000.000.000.000.000.000.000.000.000.00–
Book value4.738.0117.1123.3432.9838.8653.7067.4963.6372.3581.93+35.4%/yr
Diluted shares (M)245253259261263260259261258258255+0.6%/yr
Totals ($B)
Revenue1.72.53.04.26.27.68.99.911.012.013.0+24.2%/yr
Operating income0.00.10.61.22.92.84.33.8-0.24.24.3+95.6%/yr
Net income-0.10.32.11.22.72.33.33.6-0.54.04.0–
Free cash flow0.20.71.21.53.02.43.93.3-0.83.23.2+37.7%/yr
Buybacks0.00.00.40.20.51.40.00.41.22.01.1–
Dividends0.00.00.00.00.00.00.00.00.00.00.0–
Net cash1.12.13.23.86.77.510.913.711.212.35.3+$11.2B
Margins & returns (%)
Gross margin87.688.986.686.888.188.187.987.286.186.285.5-1.4 pts
Operating margin0.65.020.828.846.036.748.238.8-2.134.833.2+34.2 pts
Net margin-6.610.668.828.343.730.937.236.7-4.932.930.7+39.5 pts
FCF margin10.530.038.535.948.231.844.033.8-7.226.624.7+16.1 pts
ROIC––42.544.6119.491.6116.551.1-1.929.319.1–
Return on equity-9.713.047.319.331.223.223.920.6-3.321.219.0+30.9 pts
R&D % of revenue61.653.246.542.126.525.628.432.032.932.632.8-29.0 pts
Stock pay % of revenue14.111.810.78.76.95.85.55.96.35.75.2-8.4 pts
Capex % of revenue3.34.03.11.84.23.12.32.02.73.63.8+0.3 pts

Change uses 2016 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2016 base. Trend shows the fiscal years.

TTM = four quarters to Sep 30, 2026. Per-share values use diluted weighted shares.ROIC = operating income × (1 − 15.2% tax rate, the company's own over three fiscal years excluding one-offs) ÷ (equity + debt − cash and current securities). Returns show a dash when their base is negative or under 10% of revenue. Free cash flow = operating cash flow − capex. Debt is all borrowings; net cash counts long-term securities and excludes leases.

Moat

Moat scorecard

Moat score99
Strength
Confidence
Structure
Quasi-Monopoly
Durability
durable
Trajectory
stable
Pricing power
strong
Segments
  • Cystic Fibrosis CFTR Modulators96.2%
    2 claims
  • Hemoglobinopathies Gene Therapy (CASGEVY)2.3%
    2 claims
  • Acute Pain (JOURNAVX)1.5%
    1 claim
  • Rare endocrine diseases (PALSONIFY)0.0%
    1 claim

Moat claims

Applies to
Cystic Fibrosis CFTR Modulators
Confidence
Durability
durable
Trajectory
stableas of Oct 5, 2026
Why it holds

Patents protect TRIKAFTA/KAFTRIO through 2037 and ALYFTREK through 2039. Switching to ALYFTREK renews the protected franchise, but its lower royalty burden is disputed and does not itself strengthen patent control.

Why stable

TRIKAFTA protection through 2037 and ALYFTREK protection through 2039 remain intact; Q2 ALYFTREK sales of $573.6 million show uptake of the newer protected medicine, but no new legal barrier was disclosed.

Indicators
  • CF product revenue$3.3B
  • TRIKAFTA/KAFTRIO revenue$2.4B-8%
  • ALYFTREK revenue$706M+186%
Risks
  • Patent challenges can weaken exclusion; the ALYFTREK royalty arbitration can also reduce the cash retained from protected sales.
  • Older CF drugs lose protection earlier than TRIKAFTA and ALYFTREK; generic entry can change the treatment mix.
  • Breakthrough non-modulator modalities (gene therapy, mRNA) reducing modulator demand

Profile change log

  1. Nov 11, 2026 · business change

    Daniel Brennan, former Boston Scientific CFO, joined the board and Audit and Finance Committee; board expanded to eleven members. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000278/vrtx-20261020.htm (October 20, 2026).

  2. Oct 5, 2026 · analyst revision

    Extended the four existing end markets with genetic-therapy development, Medicaid outcomes-based reimbursement, non-opioid payment policy and pre-acquisition PALSONIFY adoption. Clarified low direct demand sensitivity to rates and stronger sensitivity of investment income and acquisition financing. No unverified dollar market sizes or competitor shares were added.

  3. Oct 5, 2026 · analyst revision

    Replaced the unsupported NHS annual-report citation with the 2024 agreement announcement and removed assumed exclusivity. Added ALYFTREK royalty arbitration and ToolGen manufacturing-patent risk. Replaced CF collaboration names with an investigational genetic-therapy peer and separated generic analgesic competition from Lilly pipeline optionality. Qualified the uncontrolled renal trial evidence.

  4. Oct 5, 2026 · analyst revision

    Added management, a sourced bull and bear debate, and four shared end markets. Separates non-cyclical clinical demand from reimbursement, currency, rates, regulation and acquisition risks.

  5. Oct 5, 2026 · business change

    Added the September 1 Crinetics acquisition and PALSONIFY product category, its protected molecule and competing therapies. June revenue share is zero before ownership; Q3 will first disclose the consolidated sales and purchase accounting.

  6. Oct 5, 2026 · analyst revision

    Removed the unsupported 72-75% CF market-share range: nearly three quarters of 97,000 patients is treatment penetration, not competitor share. Reclassified CASGEVY dossier exclusivity from a regulated rail to a specific legal claim, without changing strength, and removed abbreviated quotations. Added sourced trajectories and peer context.

Industry & peers

Peer map

0%10%20%30%40%50%60708090100Moat scoreIndustry medianVRTXPFE

Hover a point for its values; click a peer to compare. Dashed lines: industry medians.

CFTR modulator therapies

As of Oct 5, 2026
Quasi monopolyLow cyclicality

Medicines that improve CFTR protein function in cystic fibrosis, in the US, Europe, Australia and Canada. Excludes antibiotics, pancreatic enzymes, symptomatic care and investigational genetic cures.

  1. Vertex Pharmaceuticals
2025 leaders, no comparable shares · Vertex FY2025 Form 10-K
StocksMoatGross m.Op. m.
VRTX9985.5%33.2%
Industry median176973.1%21.8%
Sector median557661.5%17.3%
All stocks median3987653.1%20.0%

Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.

Drivers & risks

Demand drivers
  • Earlier diagnosis and approvals for younger children expand eligible treatment years.
  • Longer patient survival supports a larger population receiving chronic therapy.
  • National reimbursement agreements convert clinical eligibility into paid access.
  • New combinations can improve convenience and CFTR function, supporting franchise renewal.
  • Clinical need has low sensitivity to GDP; exchange rates have a moderate effect on multinational reported sales after hedging.
Risks
  • Payer budgets and drug-price regulation can reduce net prices even with strong clinical demand.
  • Patent invalidation or expiry opens direct copying. Royalty disputes can reduce suppliers' retained cash even when protection remains intact.
  • An effective genetic cure could replace chronic modulators, although clinical and delivery risks remain.
  • Ineligible mutations, intolerance and unequal reimbursement limit the reachable population.
  • Supply and compliance failures can interrupt treatment. Rates affect suppliers' cash income and acquisition funding; payer policy has more direct influence on sales than current tariff costs.

Bulls & bears

Key question · as of Nov 11, 2026

Can Vertex turn its CF-funded research and acquisitions into durable sales outside CF while preserving the cash generation of its core franchise?

Arguments

4 forFaded: weakening or settled6 against

What to watch

  1. 1CF portfolio, TRIKAFTA and ALYFTREK net sales, reimbursement access and ALYFTREK royalty arbitration.
  2. 2CASGEVY paid infusions versus cell collections, and JOURNAVX paid prescriptions and net sales.
  3. 3PALSONIFY net sales, post-acquisition borrowing, interest expense and cash, and research spending.
  4. 4Povetacicept approval and paid launch uptake; inaxaplin pivotal efficacy and safety.

Next check: Watch the November 30, 2026 povetacicept FDA target date, Q4 results when announced and the AMPLITUDE interim analysis expected in early 2027.

Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.

Cite or reuse this data

Free to reuse, commercially too, with a credit link. See the data license.

Moat Score 99/100 by <a href="https://www.findmymoat.com/stocks/XNAS:VRTX">Find My Moat</a> (as of September 2026)

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.